Fig. 3 –

Activity of MBLI-87, NANO and irinotecan, either alone or in combination, against control (A) and ABCG2-expressing (B and C) xenografts. Doses and schedules are detailed in Section 2. (A and B) The data at each time period were averaged. The tumour volume values were plotted against time. Differences with p values <0.05 were considered as statistically significant between two sets of xenograft volume (N = 6/group). (C) Mice were treated with either NANO or MBLI-87 in combination with irinotecan. The data were sets of tumour measurements (in sixes) at four time periods: first therapy period, first rest period, second therapy period and second rest period, for two parallel therapy conditions: MBLI-87-irinotecan (N = 5) and NANO-irinotecan (N = 6). The data at each time period were averaged and standard errors (SE) computed. A plot was made of tumour volume ± SE against time.